Andrew Dickinson - Gilead Sciences President
| GILD34 Stock | BRL 287.56 4.47 1.58% |
President
Mr. Andrew Dickinson is Executive Vice President Corporationrationrate Development and Strategy of the Company. Mr. Dickinson joined Gilead in 2016 as Senior Vice President, Corporationrationrate Development. He led the acquisitions of Kite Pharma, Inc. and Cell Design Labs, Inc., and was instrumental in reshaping Gilead approach to corporate development, increasing the volume and types of agreements that the company has entered into during his tenure. Prior to joining Gilead, Mr. Dickinson served as Global CoHead of Healthcare Investment Banking for Lazard. At Lazard, he advised on numerous, industrydefining merger and acquisition transactions, as well as many other strategic matters across the biopharmaceutical industry since 2018.
| Age | 53 |
| Tenure | 6 years |
| Phone | 650 574 3000 |
| Web | https://www.gilead.com |
Andrew Dickinson Latest Insider Activity
Tracking and analyzing the buying and selling activities of Andrew Dickinson against Gilead Sciences stock is an integral part of due diligence when investing in Gilead Sciences. Andrew Dickinson insider activity provides valuable insight into whether Gilead Sciences is net buyers or sellers over its current business cycle. Note, Gilead Sciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell Gilead Sciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Andrew Dickinson over three months ago Disposition of 3025 shares by Andrew Dickinson of Gilead Sciences subject to Rule 16b-3 |
Gilead Sciences Management Efficiency
The company has return on total asset (ROA) of 0.1045 % which means that it generated a profit of $0.1045 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.216 %, meaning that it generated $0.216 on every $100 dollars invested by stockholders. Gilead Sciences' management efficiency ratios could be used to measure how well Gilead Sciences manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 12 records | PRESIDENT Age | ||
| Robert Michael | AbbVie Inc | 53 | |
| Christopher Boerner | Bristol Myers Squibb | 52 | |
| Robin Kramer | Biogen Inc | 57 | |
| Sanjay Jariwala | Biogen Inc | N/A | |
| Laura Schumacher | AbbVie Inc | 60 | |
| Jeffrey Stewart | AbbVie Inc | 54 | |
| Ann Judge | Bristol Myers Squibb | 57 | |
| Richard DeLuca | Merck Co | 60 | |
| Timothy Richmond | AbbVie Inc | 57 | |
| Azita SalekiGerhardt | AbbVie Inc | 60 | |
| Anabella Villalobos | Biogen Inc | 64 | |
| Ginger Gregory | Biogen Inc | 55 | |
Management Performance
Gilead Sciences Leadership Team
Elected by the shareholders, the Gilead Sciences' board of directors comprises two types of representatives: Gilead Sciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Gilead. The board's role is to monitor Gilead Sciences' management team and ensure that shareholders' interests are well served. Gilead Sciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Gilead Sciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Daniel ODay, Chairman of the Board, CEO | ||
| Johanna Mercier, Chief Commercial Officer | ||
| Deborah Telman, Gen Affairs | ||
| Jyoti Mehra, Ex HR | ||
| Jacquie CFA, VP Relations | ||
| Diane Wilfong, Corp VP | ||
| Andrew Dickinson, Executive Vice President - Corporate Development and Strategy | ||
| Michael Quigley, VP Biology | ||
| Linda Higgins, VP Innovation |
Gilead Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Gilead Sciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.22 | |||
| Return On Asset | 0.1 | |||
| Profit Margin | 0.17 % | |||
| Operating Margin | 0.40 % | |||
| Current Valuation | 686.18 B | |||
| Shares Outstanding | 2.49 B | |||
| Price To Earning | 28.35 X | |||
| Price To Book | 5.30 X | |||
| Price To Sales | 21.27 X | |||
| Revenue | 27.28 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Gilead Stock
When determining whether Gilead Sciences is a strong investment it is important to analyze Gilead Sciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Gilead Sciences' future performance. For an informed investment choice regarding Gilead Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gilead Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.